Effect of duloxetine administration in patients with depressive symptoms undergoing total knee arthroplasty: A randomized controlled trial

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100054802

Enrollment

Unknown

Registered

2021-12-27

Start date

2021-12-20

Completion date

Unknown

Last updated

2022-12-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Total knee arthroplasty

Interventions

Duloxetine group:Duloxetine 60 mg daily for 7 days, starting on the day of surgery (2 hours before surgery)

Placebo group:Placebo 60 mg daily for 7 days, starting on the day of surgery (2 hours before surgery)

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: Patients 18-85 years of age requiring primary unilateral knee osteoarthritis with a 17-item Hamilton Depression Score of more than 8.

Exclusion criteria

Exclusion criteria: 1. ASA grade 4, duloxetine allergy, history of related drug use (SNRI, SSRI or other antidepressant drugs) 6 months before surgery; 2. Liver and kidney function damage, coagulation disorders, central or peripheral nerve damage, cognitive dysfunction, opioid or alcohol dependence.

Design outcomes

Primary

Measure	Time frame
Pain with ambulation;17-item Hamilton Depression Score;	—

Secondary

Measure	Time frame
Pain with knee flexion;pain at rest;Morphine consumption;Knee range of motion;American Knee Society Score;WOMAC function score;	—

Countries

China

Contacts

Public ContactZhou Zongke

West China Hospital, Sichuan University

zhouzongke@scu.edu.cn+86 18980601028

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026